Mechanisms of Susceptibility of Excitatory Neurons to Tau Pathology and Neurodegeneration in Alzheimer's disease
阿尔茨海默病中兴奋性神经元对 Tau 病理学和神经变性的易感性机制
基本信息
- 批准号:9913057
- 负责人:
- 金额:$ 78.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-01 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAffinity ChromatographyAgeAge-associated memory impairmentAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAlzheimer&aposs disease patientAlzheimer&aposs disease riskAmericanAtrophicAutopsyBacterial Artificial ChromosomesBehavioralBrainBrain regionCellsCessation of lifeChemicalsCognitive deficitsDataDevelopmentDiseaseDisease ProgressionExcitatory Amino Acid Transporter 2Expression ProfilingGene ExpressionGene Expression ProfileGenesGeneticGenetic TranscriptionGlutamate TransporterGlutamatesGoalsHeterogeneityHippocampus (Brain)HumanImmune System DiseasesImpaired cognitionImpairmentInflammationInflammation MediatorsInternal Ribosome Entry SiteInterneuronsLearningMAPT geneMediatingMemoryMemory impairmentMessenger RNAMethodologyModelingMolecularMotor CortexMusNeocortexNerve DegenerationNeurodegenerative DisordersNeurofibrillary TanglesNeuronsPathogenesisPathologyPathway AnalysisPathway interactionsPhysiologicalPlayPolyribosomesPopulationPredispositionPrefrontal CortexReporterResectedResistanceRibosomesRiluzoleRoleSocietiesSuspensionsSynapsesTauopathiesTechniquesTestingToxic effectTranslatingTreatment EfficacyValidationViralViral VectorVisual Cortexadeno-associated viral vectorage relatedassociation cortexbrain tissuecell typeeconomic impacteffective therapyentorhinal cortexexcitatory neuronexperimental studyhippocampal pyramidal neuronhuman diseasehyperphosphorylated tauindexinginduced pluripotent stem cellinhibitory neuroninnovationinsightknock-downmouse modelmutantneocorticalneural circuitneuroinflammationneuron lossneurotoxicitynew therapeutic targetnoveloverexpressionpsychologicpsychosocialpublic health relevanceresiliencesingle cell sequencingsingle-cell RNA sequencingtau Proteinstau aggregationtau mutationtherapeutic targettranscriptomicsuptake
项目摘要
Project summary
The hippocampus is important for learning and memory and is highly susceptible to aggregation of microtubule-
associated protein tau (MAPT) and neurodegeneration. Hippocampal and neocortical atrophy in Alzheimer’s disease
(AD) brains demonstrates degeneration predominantly in large glutamatergic pyramidal neurons in association cortices
while inhibitory interneurons and primary cortices are resistant to MAPT accumulation and degeneration. However, the
molecular mechanisms that cause damage and death of susceptible neurons are not understood. Developing a better
understanding of the molecular mechanisms causing vulnerability of excitatory neurons to damage and identifying
pathways that regulate tau-mediated neurodegeneration will be essential to unraveling the pathogenesis and
progression of AD and identifying potential therapeutic targets. The primary goal of this proposal is to identify pathways
that make excitatory neurons susceptible to tau accumulation and neurodegeneration, and identify potential therapeutic
targets for AD. One important limitation is the cellular heterogeneity of the mammalian brain. To overcome the cellular
heterogeneity, this proposal will innovatively use single cell RNA sequencing in fresh AD human brain tissue and viral
translating ribosome affinity purification (vTRAP) in a mouse model of tauopathy to generate transcriptional profiles of
excitatory and inhibitory neurons from vulnerable and resilient regions of the brain in the context of aging and
neurodegeneration. Global gene co-expression networks for excitatory and inhibitory neurons will be constructed
through Weighted Interaction Network Analysis (WINA) and Multiscale Embedded Gene co-Expression Network
Analysis (MEGENA). WINA and MEGENA derived modules will then be associated with AD and the top key drivers of
the modules most associated with AD will become the candidate targets for experimental validation. We will also identify
distinct and intersecting pathways from glutamate and tau mediated toxicities specifically in the pyramidal neurons of
CA1 and CA3 regions of the hippocampus. Bacterial artificial chromosome TRAP (BAC-TRAP) reporter mouse lines in
conjunction with models of glutamate dyshomeostasis (EAAT2-/-) and mutant human tau (P301S) will be used to
generate translational profiles of CA1 and CA3 regions of the hippocampus at various stages of disease progression.
Further, we will also evaluate the role of EAAT2, the major glutamate transporter, in tau accumulation, trans synaptic
tau spread, immune dysfunction and neurodegeneration, and its potential as a therapeutic target using genetic (viral
vector) and chemical (riluzole) approaches. This proposal will provide novel insights into the molecular mechanisms of
excitatory neuronal susceptibility and resilience of inhibitory neurons in AD, identify potential new therapeutic targets for
tau-mediated neurodegeneration and provide a mechanistic understanding of glutamate transporter EAAT2 as a
mediator of inflammation and spread of tau pathology. A better understanding of the underlying molecular
mechanisms of AD is crucial for the development of novel and more effective therapeutic targets. This proposal
has the potential to make a significant impact to the field of AD by uncovering novel mechanisms of disease and
identification of specific therapeutic targets.
项目摘要
海马对学习和记忆很重要,并且对微管的聚集非常敏感。
相关蛋白tau(MAPT)和神经变性。阿尔茨海默病的海马和新皮质萎缩
(AD)大脑显示变性主要发生在联合皮质中的大海马锥体神经元
而抑制性中间神经元和初级皮质对MAPT积累和退化具有抗性。但
引起易感神经元损伤和死亡的分子机制尚不清楚。开发更好的
了解兴奋性神经元易受损伤的分子机制,
调节tau蛋白介导的神经变性的途径对于阐明发病机制和
AD的进展和识别潜在的治疗靶点。该提案的主要目标是确定
使兴奋性神经元对tau蛋白积聚和神经变性敏感,并确定潜在的治疗方法,
AD的目标。一个重要的限制是哺乳动物大脑的细胞异质性。为了克服细胞
异质性,该提案将创新性地使用单细胞RNA测序在新鲜的AD人脑组织和病毒
翻译核糖体亲和纯化(vTRAP),以产生Tau蛋白病的转录谱。
兴奋性和抑制性神经元从脆弱的和有弹性的大脑区域的背景下老化,
神经变性将构建兴奋性和抑制性神经元的全局基因共表达网络
通过加权相互作用网络分析(WINA)和多尺度嵌入式基因共表达网络
分析(MEGENA)。WINA和MEGENA衍生模块将与AD以及
与AD最相关的模块将成为实验验证的候选目标。我们还将确定
谷氨酸和tau蛋白介导的毒性的不同和交叉的途径,特别是在锥体神经元中,
海马的CA 1和CA 3区域。细菌人工染色体TRAP(BAC-TRAP)报告基因小鼠系,
结合谷氨酸稳态异常(EAAT 2-/-)和突变的人tau(P301 S)模型,
在疾病进展的不同阶段产生海马CA 1和CA 3区域的翻译谱。
此外,我们还将评估EAAT 2,主要的谷氨酸转运蛋白,在tau蛋白积累,跨突触
tau扩散、免疫功能障碍和神经变性,以及其作为使用遗传(病毒)治疗靶点的潜力
载体)和化学(利鲁唑)方法。这一建议将提供新的见解的分子机制,
兴奋性神经元的易感性和弹性的抑制性神经元在AD中,确定潜在的新的治疗靶点,
tau蛋白介导的神经退行性变,并提供了谷氨酸转运蛋白EAAT 2作为一种
炎症介质和tau病理学扩散。更好地了解潜在的分子
研究AD的发病机制对于开发新的和更有效的治疗靶点至关重要。这项建议
通过揭示疾病的新机制,有可能对AD领域产生重大影响,
确定特定的治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ana C. Pereira其他文献
Neocortical tau propagation is a mediator of clinical heterogeneity in Alzheimer’s disease
新皮质 tau 蛋白传播是阿尔茨海默病临床异质性的介质
- DOI:
10.1038/s41380-025-02998-y - 发表时间:
2025-04-16 - 期刊:
- 影响因子:10.100
- 作者:
Anjalika Chongtham;Aarthi Ramakrishnan;Marissa Farinas;Diede W. M. Broekaart;Joon Ho Seo;Carolyn W. Zhu;Mary Sano;Li Shen;Ana C. Pereira - 通讯作者:
Ana C. Pereira
Multivariate Statistical Monitoring of Wine Ageing Processes
葡萄酒陈酿过程的多元统计监测
- DOI:
10.1016/s1570-7946(10)28042-2 - 发表时间:
2010 - 期刊:
- 影响因子:0
- 作者:
Ana C. Pereira;M. Reis;P. Saraiva;J. Marques - 通讯作者:
J. Marques
The Influence of Transport and Storage Conditions on Beer Stability—a Systematic Review
- DOI:
10.1007/s11947-022-02790-8 - 发表时间:
2022-03-05 - 期刊:
- 影响因子:5.800
- 作者:
Dayana Aguiar;Ana C. Pereira;José C. Marques - 通讯作者:
José C. Marques
(±)-licarin A and its semi-synthetic derivatives: in vitro and in silico evaluation of trypanocidal and schistosomicidal activities.
(±)-利卡林 A 及其半合成衍生物:杀锥虫和杀血吸虫活性的体外和计算机评估。
- DOI:
- 发表时间:
2020 - 期刊:
- 影响因子:2.7
- 作者:
Vanderlisa Rita Meleti;V. Esperandim;L. G. B. Flauzino;Anna Helena Prizantelli;L. A. Paula;L. Magalhães;W. Cunha;Rosangela S. Laurentiz;Ana P. R. Pissurno;N. Nanayakkara;Ana C. Pereira;J. Bastos;R. Parreira;R. Orenha;M. E. e Silva - 通讯作者:
M. E. e Silva
Effect of the dibenzylbutyrolactone lignan (-)-hinokinin on doxorubicin and methyl methanesulfonate clastogenicity in V79 Chinese hamster lung fibroblasts.
二苄基丁内酯木脂素 (-)-日桧素对 V79 中国仓鼠肺成纤维细胞中阿霉素和甲磺酸甲酯致裂性的影响。
- DOI:
- 发表时间:
2010 - 期刊:
- 影响因子:0
- 作者:
F. A. Resende;I. M. Tomazella;L. C. Barbosa;M. Ponce;R. Furtado;Ana C. Pereira;J. Bastos;M. L. Andrade E Silva;D. Tavares - 通讯作者:
D. Tavares
Ana C. Pereira的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ana C. Pereira', 18)}}的其他基金
Mechanisms of Susceptibility of Excitatory Neurons to Tau Pathology and Neurodegeneration in Alzheimer's disease
阿尔茨海默病中兴奋性神经元对 Tau 病理学和神经变性的易感性机制
- 批准号:
10565899 - 财政年份:2020
- 资助金额:
$ 78.68万 - 项目类别:
Mechanisms of Susceptibility of Excitatory Neurons to Tau Pathology and Neurodegeneration in Alzheimer's disease
阿尔茨海默病中兴奋性神经元对 Tau 病理学和神经变性的易感性机制
- 批准号:
10343723 - 财政年份:2020
- 资助金额:
$ 78.68万 - 项目类别:
Mechanisms of Susceptibility of Excitatory Neurons to Tau Pathology and Neurodegeneration in Alzheimer's disease
阿尔茨海默病中兴奋性神经元对 Tau 病理学和神经变性的易感性机制
- 批准号:
10092063 - 财政年份:2020
- 资助金额:
$ 78.68万 - 项目类别:
Mechanisms of Obstructive Sleep Apnea in Tau Pathophysiology, Risk and Progression of Alzheimer's Disease
阻塞性睡眠呼吸暂停在 Tau 病理生理学、阿尔茨海默病风险和进展中的机制
- 批准号:
10408756 - 财政年份:2019
- 资助金额:
$ 78.68万 - 项目类别:
Mechanisms of Obstructive Sleep Apnea in Tau Pathophysiology, Risk and Progression of Alzheimer's Disease
阻塞性睡眠呼吸暂停在 Tau 病理生理学、阿尔茨海默病风险和进展中的机制
- 批准号:
10629413 - 财政年份:2019
- 资助金额:
$ 78.68万 - 项目类别:
Mechanisms of Obstructive Sleep Apnea in Tau Pathophysiology, Risk and Progression of Alzheimer's Disease
阻塞性睡眠呼吸暂停在 Tau 病理生理学、阿尔茨海默病风险和进展中的机制
- 批准号:
10160739 - 财政年份:2019
- 资助金额:
$ 78.68万 - 项目类别:
Enhancing Glutamate Transport in Age-related Cognitive Decline and Alzheimer's Disease
增强谷氨酸转运以治疗与年龄相关的认知衰退和阿尔茨海默病
- 批准号:
9228807 - 财政年份:2016
- 资助金额:
$ 78.68万 - 项目类别:
相似海外基金
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10506915 - 财政年份:2021
- 资助金额:
$ 78.68万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 78.68万 - 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
- 批准号:
1746198 - 财政年份:2018
- 资助金额:
$ 78.68万 - 项目类别:
Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
- 批准号:
512537-2017 - 财政年份:2017
- 资助金额:
$ 78.68万 - 项目类别:
University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
- 批准号:
1404605 - 财政年份:2014
- 资助金额:
$ 78.68万 - 项目类别:
Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
- 批准号:
1263713 - 财政年份:2013
- 资助金额:
$ 78.68万 - 项目类别:
Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
- 批准号:
425749-2012 - 财政年份:2012
- 资助金额:
$ 78.68万 - 项目类别:
Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
- 批准号:
1159886 - 财政年份:2012
- 资助金额:
$ 78.68万 - 项目类别:
Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
- 批准号:
19560760 - 财政年份:2007
- 资助金额:
$ 78.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
- 批准号:
234753-2000 - 财政年份:2003
- 资助金额:
$ 78.68万 - 项目类别:
Collaborative Research and Development Grants














{{item.name}}会员




